PPAR Agonists and Cardiovascular Disease in Diabetes
Open Access
- 2 January 2008
- journal article
- review article
- Published by Wiley in PPAR Research
- Vol. 2008 (1) , 245410
Abstract
Peroxisome proliferators activated receptors (PPARs) are ligand‐activated nuclear transcription factors that play important roles in lipid and glucose homeostasis. To the extent that PPAR agonists improve diabetic dyslipidaemia and insulin resistance, these agents have been considered to reduce cardiovascular risk. However, data from murine models suggests that PPAR agonists also have independent anti‐atherosclerotic actions, including the suppression of vascular inflammation, oxidative stress, and activation of the renin angiotensin system. Many of these potentially anti‐atherosclerotic effects are thought to be mediated by transrepression of nuclear factor‐kB, STAT, and activator protein‐1 dependent pathways. In recent clinical trials, PPARα agonists have been shown to be effective in the primary prevention of cardiovascular events, while their cardiovascular benefit in patients with established cardiovascular disease remains equivocal. However, the use of PPARγ agonists, and more recently dual PPARα/γ coagonists, has been associated with an excess in cardiovascular events, possibly reflecting unrecognised fluid retention with potent agonists of the PPARγ receptor. Newer pan agonists, which retain their anti‐atherosclerotic activity without weight gain, may provide one solution to this problem. However, the complex biologic effects of the PPARs may mean that only vascular targeted agents or pure transrepressors will realise the goal of preventing atherosclerotic vascular disease.Keywords
This publication has 129 references indexed in Scilit:
- Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient miceAtherosclerosis, 2007
- Increase in weight induced by muraglitazar, a dual PPARα/γ agonist, in db/db mice: adipogenesis/or oedema?British Journal of Pharmacology, 2007
- Urothelial Carcinogenesis in the Urinary Bladder of Male Rats Treated with Muraglitazar, a PPARα/γ Agonist: Evidence for Urolithiasis as the Inciting Event in the Mode of ActionToxicologic Pathology, 2006
- Effects of bezafibrate on the expression of endothelial nitric oxide synthase gene and its mechanisms in cultured bovine endothelial cellsAtherosclerosis, 2006
- Thiazolidinediones inhibit TNFα induction of PAI-1 independent of PPARγ activationBiochemical and Biophysical Research Communications, 2005
- High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) studyAmerican Heart Journal, 2004
- Effect of Rosiglitazone Treatment on Soluble CD40L in Patients With Type 2 Diabetes and Coronary Artery DiseaseCirculation, 2003
- Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effectLife Sciences, 2000
- Expression of Peroxisome Proliferator-Activated Receptor α (PPARα) in Primary Cultures of Human Vascular Endothelial CellsBiochemical and Biophysical Research Communications, 1998
- Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor.Journal of Clinical Investigation, 1995